The Impact of Pre-Chemotherapy Body Composition and Immunonutritional Markers on Chemotherapy Adherence in Stage III Colorectal Cancer Patients

• Published in: Journal of clinical medicine Vol. 12; no. 4; p. 1423
• Main Authors: Lee, Soohyeon, Kang, Dong Hyun, Ahn, Tae Sung, Kim, Seung Soo, Yun, Jong Hyuk, Kim, Hyun Jung, Seo, Seoung Hee, Kim, Tae Wan, Kong, Hye Jeong, Baek, Moo Jun
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 10.02.2023; MDPI
• Subjects: Biological markers; Biomarkers; Body composition; Body mass index; Cancer; Cancer therapies; Chemotherapy; Clinical medicine; Colorectal cancer; Disease; Drug dosages; Drug therapy; Health aspects; Inflammation; Lymphocytes; Malnutrition; Medical prognosis; Medical records; Mortality; Musculoskeletal system; Neutrophils; Nutrition; Nutritional status; Oncology, Experimental; Patient compliance; Patient outcomes; Patients; Regression analysis; Surgery; South Korea; body composition; relative dose intensity; colorectal cancer; chemotherapy adherence
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12041423

Patients with colorectal cancer (CRC) often fail to complete full-course chemotherapy with a standard dose due to various reasons. This study aimed to determine whether body composition affects chemotherapy adherence in patients with CRC. The medical records of 107 patients with stage III CRC who underwent adjuvant folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy at a single center between 2014 and 2018 were analyzed retrospectively. Blood test results for selected immunonutritional markers were analyzed and body composition was measured through computed tomography. Univariate and multivariate analyses were performed on low and high relative dose intensity (RDI) groups, based on an RDI of 0.85. In the univariate analysis, a higher skeletal muscle index was correlated with a higher RDI ( = 0.020). Psoas muscle index was also higher in patients with high RDI than in those with low RDI ( = 0.026). Fat indices were independent of RDI. Multivariate analysis was performed for the aforementioned factors and results showed that age ( = 0.028), white blood cell count ( = 0.024), and skeletal muscle index ( = 0.025) affected RDI. In patients with stage III CRC treated with adjuvant FOLFOX chemotherapy, a decrease in RDI was related to age, white blood cell count, and skeletal muscle index. Therefore, if we adjust the drug dosage in consideration of these factors, we can expect an increased treatment efficiency in patients by increasing chemotherapy compliance.